BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31989786)

  • 1. Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.
    Kehl KL; Hassett MJ; Schrag D
    Cancer Med; 2020 Mar; 9(6):2019-2029. PubMed ID: 31989786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer.
    Hung A; Lee KM; Alba PR; Li Y; Gao AZ; Hintze BJ; Efimova OV; Shenolikar R; Pavilack M; Simmons D; Kelley MJ; Lynch JA; Reed SD
    Cancer Treat Res Commun; 2021; 27():100327. PubMed ID: 33549984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
    Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
    Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
    BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal patterns of care and outcomes of non-small cell lung cancer patients in the United States diagnosed in 1996, 2005, and 2010.
    Kaniski F; Enewold L; Thomas A; Malik S; Stevens JL; Harlan LC
    Lung Cancer; 2017 Jan; 103():66-74. PubMed ID: 28024699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
    Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
    Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
    Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy.
    Stenehjem D; Lubinga S; Betts KA; Tang W; Jenkins M; Yuan Y; Hartman J; Rao S; Lam J; Waterhouse D
    Future Oncol; 2021 Aug; 17(22):2940-2949. PubMed ID: 33849296
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
    Schwartzberg L; Korytowsky B; Penrod JR; Zhang Y; Le TK; Batenchuk C; Krug L
    Clin Lung Cancer; 2019 Jul; 20(4):287-296.e4. PubMed ID: 31130450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States.
    Enewold L; Thomas A
    PLoS One; 2016; 11(6):e0156728. PubMed ID: 27294665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
    Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
    JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.
    Huo J; Ray-Zack MD; Shan Y; Chamie K; Boorjian SA; Kerr P; Jana B; Freedland SJ; Kamat AM; Mehta HB; Williams SB
    Eur Urol Oncol; 2019 Sep; 2(5):497-504. PubMed ID: 31411998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
    Carroll R; Bortolini M; Calleja A; Munro R; Kong S; Daumont MJ; Penrod JR; Lakhdari K; Lacoin L; Cheung WY
    BMC Cancer; 2022 Mar; 22(1):255. PubMed ID: 35264135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.
    Macleod LC; Yabes JG; Yu M; Fam MM; Hale NE; Turner RM; Lopa SH; Gingrich JR; Borza T; Skolarus TA; Davies BJ; Jacobs BL
    Urol Oncol; 2019 Jul; 37(7):462-469. PubMed ID: 31053530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
    Pan IW; Mallick R; Dhanda R; Nadler E
    Lung Cancer; 2013 Dec; 82(3):469-76. PubMed ID: 24396885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network.
    Ritzwoller DP; Carroll NM; Delate T; Hornbrook MC; Kushi L; Aiello Bowles EJ; Freml JM; Huang K; Loggers ET
    Lung Cancer; 2012 Dec; 78(3):245-52. PubMed ID: 23022316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
    Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
    JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.
    Waliany S; Neal JW; Engel-Nitz N; Lam C; Lin F; Park L; Le L; Nagasaka M
    Clin Lung Cancer; 2024 Jun; 25(4):319-328.e1. PubMed ID: 38403548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
    Ruiz-Patiño A; Arrieta O; Cardona AF; Martín C; Raez LE; Zatarain-Barrón ZL; Barrón F; Ricaurte L; Bravo-Garzón MA; Mas L; Corrales L; Rojas L; Lupinacci L; Perazzo F; Bas C; Carranza O; Puparelli C; Rizzo M; Ruiz R; Rolfo C; Archila P; Rodríguez J; Sotelo C; Vargas C; Carranza H; Otero J; Pino LE; Ortíz C; Laguado P; Rosell R;
    Thorac Cancer; 2020 Feb; 11(2):353-361. PubMed ID: 31828967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practice Patterns and Outcomes in Elderly Stage I Non-Small-cell Lung Cancer: A 2004 to 2012 SEER Analysis.
    Dalwadi SM; Szeja SS; Bernicker EH; Butler EB; Teh BS; Farach AM
    Clin Lung Cancer; 2018 Mar; 19(2):e269-e276. PubMed ID: 29208356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.